This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
Bausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?
by Zacks Equity Research
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Sell Stocks for December 9th
by Zacks Equity Research
ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.
Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered
by Zacks Equity Research
Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.
Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Bausch (BHC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.
Why Is Bausch (BHC) Up 23% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
by Zacks Equity Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down
by Zacks Equity Research
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 4.76% and 21.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
by Zacks Equity Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Bausch Health (BHC) closed at $4.59, marking a -0.65% move from the previous day.
Bausch (BHC) Loses 39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Bausch (BHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Bausch (BHC) Suspends IPO Plans for Solta Medical
by Zacks Equity Research
Bausch (BHC) suspends its plans for the initial public offering of its Solta Medical business in light of the challenging market conditions and other factors.
Why Is Bausch (BHC) Down 11.2% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for Bausch (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.
New Strong Sell Stocks for May 19th
by Zacks Equity Research
ASX, CNMD, and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2022.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More
by Kanishka Das
Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?